ROCKVILLE, Md. and TOKYO, July 30, 2026
Kaigene has entered into an exclusive licensing agreement with Taisho Pharmaceutical Co., Ltd. to develop and commercialize KG006, its next-generation FcRn inhibitor for autoimmune diseases, in Japan. Under the agreement, Taisho will receive exclusive rights to clinically develop, obtain regulatory approval for, and commercialize KG006 within the Japanese market, while Kaigene will receive a $5 million upfront payment and become eligible for up to $22 million and ¥57.5 billion (approximately $351 million) in development, regulatory, and commercial milestone payments, in addition to tiered royalties on future product sales. The strategic partnership also establishes the framework for a three-way multi-regional clinical trial (MRCT) collaboration involving Kaigene, Taisho, and Celltrion, aimed at accelerating global development of the investigational therapy. The agreement strengthens Kaigene’s expanding global autoimmune portfolio while positioning KG006 as a potential best-in-class FcRn inhibitor for antibody-mediated autoimmune diseases.
Strategic Licensing Agreement Expands Global Development of KG006
The licensing agreement marks an important milestone in Kaigene’s global commercialization strategy by securing a highly experienced pharmaceutical partner for the Japanese market. Under the terms of the collaboration, Taisho Pharmaceutical assumes full responsibility for clinical development, regulatory submissions, and commercialization of KG006 in Japan while leveraging its extensive experience in autoimmune disease therapies. Beyond the $5 million upfront payment, Kaigene is eligible to receive substantial milestone payments tied to clinical progress, regulatory approvals, and commercial performance, potentially exceeding $370 million in total value when combined with milestone payments and royalties. The agreement complements Kaigene’s previously announced strategic alliance with Celltrion, which retains commercialization rights for KG006 outside Japan and Greater China. Together, the partnerships establish a coordinated global development strategy designed to streamline regulatory progress and accelerate worldwide patient access.
Next-Generation FcRn Inhibitor Targets Autoimmune Diseases
KG006, also known as CT-P77 within Celltrion’s development program, is a next-generation human neonatal Fc receptor (FcRn) inhibitor engineered with a novel antibody structure designed to deliver deep pathogenic antibody degradation, prolonged therapeutic durability, and convenient subcutaneous self-administration. FcRn inhibitors represent one of the fastest-growing therapeutic classes in autoimmune medicine, offering the ability to reduce disease-causing antibodies across a broad range of antibody-mediated autoimmune disorders. Kaigene believes KG006 has the potential to become a best-in-class therapy by combining potent efficacy with improved dosing convenience and broader clinical applicability. The company’s proprietary PDEG™ (Pathogenic Antibody Degrader) platform further supports its pipeline by selectively degrading pathogenic antibodies while suppressing the B cells responsible for producing harmful autoantibodies, providing an innovative approach to immune modulation.
Advertisement
Global Collaboration Strengthens Autoimmune Innovation Pipeline
The collaboration creates a powerful international development network that combines Kaigene’s antibody engineering expertise, Taisho Pharmaceutical’s established commercialization capabilities, and Celltrion’s global clinical development infrastructure. Subject to regulatory planning, the agreement is expected to support Taisho’s participation in the planned Phase 3 Multi-Regional Clinical Trial (MRCT) led by Celltrion, enabling synchronized clinical development across multiple regions. The three-company alliance aims to accelerate regulatory approvals, optimize global clinical trial execution, and explore additional autoimmune disease indications beyond the initial development program. As demand continues to grow for innovative therapies targeting complex autoimmune disorders, the partnership reinforces industry investment in next-generation biologics, strategic licensing agreements, and collaborative drug development models capable of bringing advanced treatments to patients more efficiently. With its expanding immunology pipeline and novel antibody technologies, Kaigene continues strengthening its position within the rapidly evolving autoimmune therapeutics market.
Source: Kaigene, Taisho Pharmaceutical press release
